Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Compounded Drugs May Return To Supreme Court After 5th Circuit Backs FDAMA

Executive Summary

The Supreme Court could once again be asked to consider FDA's authority over compounded drugs following an appeals court ruling that found the products are considered "new drugs" but are entitled to safe harbor protections under the FDA Modernization Act
Advertisement

Related Content

Congress’ New Drug Safety Priority: FDA’s Authority Over Compounders
FDA’s Compounding Oversight: What Price Safety?
Wyeth Loses Citizen Petition Battle But Wins War Over Compounded Hormones
Supreme Court Reaffirms Least Restrictive Standard For Ad Controls
Supreme Court Reaffirms Least Restrictive Standard For Ad Controls
Advertisement
UsernamePublicRestriction

Register

PS049988

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel